(Q53548387)
Statements
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. (English)
Sarosdy MF
Schellhammer PF
Soloway MS
Vogelzang NJ
Crawford ED
Presti J
Chodak GW
Mitchell P
Porter L
1 May 1999
83
7
801-806
1 reference